Healthcare Mar 01, 2022 02:19 PM (GMT+8) · EqualOcean
The China food and drug administration has accepted the application for marketing license of its autologous chimeric antigen receptor T ("car-t") cell immunotherapy product benoda (Ricky orenzai injection) for the treatment of patients with recurrent or refractory follicular lymphoma. This is the second marketing license application submitted by Yaoming junuo for benoda, and is expected to become the first cell therapy product approved for the treatment of R / R FL patients in China.